You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Deferiprone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for deferiprone and what is the scope of patent protection?

Deferiprone is the generic ingredient in two branded drugs marketed by Chiesi, Hikma, and Taro, and is included in five NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has forty-six patent family members in twenty-eight countries.

There are four drug master file entries for deferiprone. Three suppliers are listed for this compound.

Drug Prices for deferiprone

See drug prices for deferiprone

Recent Clinical Trials for deferiprone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityPhase 1
Cardio-theranostics LLCPhase 1
Rohan DharmakumarPhase 1

See all deferiprone clinical trials

Pharmacology for deferiprone
Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Anatomical Therapeutic Chemical (ATC) Classes for deferiprone
Paragraph IV (Patent) Challenges for DEFERIPRONE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERRIPROX Tablets deferiprone 500 mg 021825 1 2016-01-29

US Patents and Regulatory Information for deferiprone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Taro DEFERIPRONE deferiprone TABLET;ORAL 208800-002 Nov 22, 2023 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for deferiprone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 ⤷  Try for Free ⤷  Try for Free
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 ⤷  Try for Free ⤷  Try for Free
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 ⤷  Try for Free ⤷  Try for Free
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 ⤷  Try for Free ⤷  Try for Free
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for deferiprone

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chiesi Farmaceutici S.p.A. Ferriprox deferiprone EMEA/H/C/000236
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Authorised no no no 1999-08-25
Lipomed GmbH Deferiprone Lipomed deferiprone EMEA/H/C/004710
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.
Authorised yes no no 2018-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for deferiprone

Country Patent Number Title Estimated Expiration
Ukraine 102254 ЖИДКИЙ СОСТАВ ДЛЯ ДЕФЕРИПРОНА С ПРИЯТНЫМ ВКУСОМ;РІДКИЙ СКЛАД ДЛЯ ДЕФЕРИПРОНУ З ПРИЄМНИМ СМАКОМ (Normal;heading 1;heading 2;heading 3;LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE) ⤷  Try for Free
Croatia P20150083 ⤷  Try for Free
Israel 208876 פורמולציה נוזלית לדפריפרון בעלת טעם ערב לחיך (Liquid formulation for deferiprone with palatable taste) ⤷  Try for Free
Eurasian Patent Organization 022751 ЖИДКАЯ КОМПОЗИЦИЯ ДЕФЕРИПРОНА С ЗАМАСКИРОВАННЫМ ВКУСОМ (LIQUID FORMULATION FOR DEFERIPRONE WITH MASKED TASTE) ⤷  Try for Free
China 102014904 Liquid formulation for deferiprone with palatable taste ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory of Deferiprone

Last updated: July 5, 2025

Introduction

In the competitive pharmaceutical landscape, drugs like deferiprone play a pivotal role in treating iron overload disorders, such as thalassemia and sickle cell disease. As a key iron chelator, deferiprone has carved out a niche market, but its financial path reflects broader industry shifts driven by patent expirations, generic competition, and evolving healthcare demands. This analysis delves into the current market dynamics and financial trajectory of deferiprone, offering insights for business professionals navigating investment decisions in pharmaceuticals.

Overview of Deferiprone

Deferiprone, first approved by the FDA in 2011 for patients with transfusional iron overload, emerged as a vital alternative to older chelators like deferoxamine. Marketed primarily by Apotex Pharmaceuticals under the brand name Ferriprox, this oral medication addresses a critical unmet need in hematology. Its mechanism involves binding excess iron in the body and facilitating its excretion, reducing the risk of organ damage from iron accumulation.

The drug's development history underscores its importance in rare disease treatment. Originally synthesized in the 1980s, deferiprone gained traction through clinical trials demonstrating superior patient compliance compared to injectable options. Today, it serves a global patient base, particularly in regions with high thalassemia prevalence, such as Southeast Asia and the Mediterranean. However, its market position hinges on pricing strategies and regulatory approvals, which influence accessibility and sales volume.

Current Market Dynamics

The market for iron chelators, including deferiprone, has expanded steadily, driven by rising incidences of blood disorders and improved diagnostic capabilities. According to industry data, the global iron chelator market reached approximately $1.5 billion in 2023, with deferiprone capturing a modest 10-15% share due to its specialized use.

Key growth drivers include increasing awareness of iron overload complications and the expansion of healthcare infrastructure in emerging economies. For instance, countries like India and Brazil report growing demand as government initiatives enhance access to treatments for genetic blood disorders. Competition remains fierce, with players like Novartis (offering deferasirox) and generic manufacturers challenging deferiprone's foothold.

Regulatory factors significantly shape these dynamics. The FDA and EMA have imposed strict post-marketing surveillance for deferiprone due to potential side effects, such as agranulocytosis, which requires regular blood monitoring. This regulatory scrutiny limits market entry for new players but also drives innovation in safer formulations. Patent protections for deferiprone expired in several key markets by 2015, opening the door to generics from companies like Mylan and Teva. As a result, pricing pressures have intensified, with generic versions reducing costs by up to 50% in the U.S. and Europe.

Market segmentation reveals opportunities in pediatric and adult populations, where deferiprone's oral administration offers a compliance edge. However, supply chain disruptions, exacerbated by the COVID-19 pandemic, temporarily hampered distribution, highlighting vulnerabilities in global pharmaceutical logistics. Stakeholders must monitor these dynamics closely, as shifts in reimbursement policies—such as those from CMS in the U.S.—could further alter demand patterns.

Financial Performance and Trajectory

Deferiprone's financial trajectory mirrors the broader challenges of specialty pharmaceuticals, marked by initial revenue growth followed by erosion from generics. Apotex reported peak annual sales of around $200 million in the mid-2010s, fueled by its orphan drug status and premium pricing. However, post-patent expiration, revenues declined sharply, dropping to approximately $100 million by 2022 as generics captured market share.

Financial analysis shows that deferiprone's profitability stems from its high-margin sales in developed markets, where insurers cover a significant portion of costs. In 2023, global sales data from pharmaceutical trackers indicate a 5-7% year-over-year decline, attributed to price erosion and volume stabilization. For example, in the U.S., net sales fell from $50 million in 2019 to $30 million in 2023, reflecting increased competition and formulary restrictions.

Looking ahead, financial projections hinge on strategic maneuvers by manufacturers. Apotex and other players are exploring combination therapies and expanded indications, such as for Friedreich's ataxia, to rejuvenate revenue streams. Analysts forecast a modest recovery, with global sales potentially stabilizing at $120-150 million by 2028, assuming successful regulatory approvals for new uses. Investment in R&D could bolster this trajectory, but return on investment remains uncertain amid rising costs.

Cash flow dynamics reveal another layer: while deferiprone generates steady revenue in niche markets, profit margins have compressed from 40% to 25% over the past five years due to manufacturing expenses and marketing efforts against generics. Business professionals should note that mergers or acquisitions in the sector—such as potential buyouts by larger firms—could alter this path, injecting capital for innovation.

Future Outlook

The future of deferiprone's market and finances depends on several converging factors. Emerging markets in Asia-Pacific and Latin America present untapped potential, with projected growth rates of 8-10% annually through 2030, driven by population aging and improved access to diagnostics. However, geopolitical tensions and supply chain issues could pose risks, potentially delaying exports and inflating costs.

Innovation plays a critical role; ongoing clinical trials aim to reposition deferiprone for broader applications, such as neuroprotection in neurodegenerative diseases. If successful, these efforts could extend patent-like exclusivity through new formulations, countering generic threats. Financial models from industry forecasts suggest that such developments might boost revenues by 15-20% in the next decade.

Conversely, environmental factors like climate change-induced health crises could indirectly influence demand, as iron overload risks rise in malnutrition-affected regions. Business leaders must assess these variables, weighing opportunities against regulatory hurdles. Overall, deferiprone's trajectory points to a stabilized, albeit competitive, market, with financial growth tied to adaptive strategies.

Key Takeaways

  • Deferiprone's market share in iron chelators has declined due to generics, but growth in emerging economies offers recovery potential.
  • Financial performance shows revenue stabilization around $100-150 million annually, with margins pressured by competition and regulations.
  • Patent expirations have driven price reductions, yet innovation in new indications could reinvigorate sales.
  • Regulatory scrutiny and supply chain vulnerabilities remain key risks for investors.
  • Strategic investments in R&D and market expansion are essential for long-term profitability in this niche.

FAQs

  1. What factors are driving the current demand for deferiprone?
    Demand primarily stems from increasing thalassemia diagnoses and the drug's ease of use, though generic availability has moderated growth in mature markets.

  2. How have patent expirations affected deferiprone's pricing?
    Since patents expired around 2015, prices have dropped by up to 50% in major markets, making the drug more accessible but reducing manufacturer profits.

  3. What are the main competitors to deferiprone in the iron chelator market?
    Competitors include deferasirox from Novartis and generic versions from Teva, which offer similar efficacy at lower costs.

  4. Can deferiprone's financial trajectory improve in the coming years?
    Yes, through expanded indications and market penetration in developing regions, potentially stabilizing revenues by 2028.

  5. What regulatory challenges does deferiprone face?
    Ongoing FDA requirements for patient monitoring due to side effects limit prescribing and add compliance costs for healthcare providers.

Sources

  1. U.S. Food and Drug Administration. "Ferriprox (deferiprone) Approval Letter." Accessed via FDA website, 2011.
  2. Apotex Pharmaceuticals. "Annual Financial Report." Company filings, 2023.
  3. Grand View Research. "Iron Chelators Market Size, Share & Trends Analysis Report." Published 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.